Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy-Reference-Cited by-同舟云学术

Impact of comorbidities on outcomes in patients with advanced head and neck cancer undergoing immunotherapy

Published:2023-09-08 Issue:11 Volume:45 Page:2789-2797
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Guller Meytal¹²³⁴,Cooper Dylan J.¹²^ORCID,Alkhatib Hosam⁴,Suru Aditya⁵,Blancaflor Angelo⁴,Maroun Christopher A.³⁴,Tham Tristan¹^ORCID,Allen Hailey³⁴,Mazzara Eden¹²,Thomas Jerin¹²,Amin Neha³⁴^ORCID,Wu Evan⁶,Eisele David W.⁴,Fakhry Carole⁴⁶,Pardoll Drew³⁶,Seiwert Tanguy Y.³⁶,Zhu Gangcai³⁴,Mandal Rajarsi¹²³⁴

Affiliation:

1. Department of Otolaryngology – Head and Neck Surgery Zucker School of Medicine at Hofstra/Northwell Hempstead New York USA

2. The Feinstein Institutes for Medical Research Manhasset New York USA

3. Bloomberg–Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Baltimore Maryland USA

4. Department of Otolaryngology – Head and Neck Surgery Johns Hopkins University Baltimore Maryland USA

5. Department of Chemical and Biomolecular Engineering Johns Hopkins University Baltimore Maryland USA

6. Department of Oncology Johns Hopkins University Baltimore Maryland USA

Abstract

AbstractObjectivesTo explore the impact of pre‐existing comorbidities on immunotherapy response, overall and progression‐free survival, and immune‐related adverse events (irAEs) of patients with advanced head and neck cancer (HNC) treated with immunotherapy.Patients and methodsNinety‐three patients treated with immunotherapy were identified and stratified into comorbidity absent or present (CCI < 1 and CCI ≥ 1, respectively) cohorts, and clinical outcomes were compared between these two groups.ResultsPatients with no comorbidities had longer overall survival (aHR = 2.74, 95% CI [1.18, 6.40], p = 0.02) and progression‐free survival (aHR = 2.07, 95% CI [1.03, 4.16], p = 0.04) and a higher tumor response rate (32% in CCI < 1 vs. 14% in CC ≥ 1, p = 0.05). Risk for irAEs was higher in the comorbidity absent group (p = 0.05).ConclusionComorbidity should be considered as a significant prognostic factor in clinical decision‐making for patients with advanced HNC undergoing immunotherapy.

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27502

Reference26 articles.

1. Prevalence of Multiple Chronic Conditions Among Medicare Beneficiaries, United States, 2010

2. Assessment of the impact of comorbidity on the survival of cancer patients treated by palliative care teams

3. Evaluation of comorbidity in 9388 head and neck cancer patients: A national cohort study from the DAHANCA database

4. The Impact of Comorbidity on Survival in Patients With Head and Neck Squamous Cell Carcinoma: A Nationwide Case-Control Study Spanning 35 Years

5. Immunotherapy for head and neck cancer: Recent advances and future directions